Menu Close

Korea’s Green Cross Cell sets up joint venture with U.S. Liminatus Pharma

The JV will be responsible for the commercial development, clinical research, and marketing approval activities for GCC CAR-T, a form of cell therapy patented by Liminatus Pharma, under exclusive rights in Korea and China. Liminatus Pharma also agreed to …

뉴스 수집 시각 : 2018-07-26T10:42:00.000Z
뉴스 본문 보기 : http://pulsenews.co.kr/view.php?year=2018&no=467616